Due to changes in the collection and availability of data on COVID-19 this page will no longer be updated. The webpage will no longer be available as of 11 May 2023. On-going, reliable sources of data for COVID-19 are available via the COVID-19 dashboard, Office for National Statistics, and the UKHSA This page provides a weekly summary of data on deaths related to COVID-19 published by NHS England and the Office for National Statistics. More frequent reporting on COVID-19 deaths is now available here, alongside data on cases, hospitalisations, and vaccinations. This update contains data on deaths related to COVID-19 from: NHS England COVID-19 Daily Deaths - last updated on 28 June 2022 with data up to and including 27 June 2022. ONS weekly deaths by Local Authority - last updated on 16 August 2022 with data up to and including 05 August 2022. Summary notes about each these sources are provided at the end of this document. Note on interpreting deaths data: statistics from the available sources differ in definition, timing and completeness. It is important to understand these differences when interpreting the data or comparing between sources. Weekly Key Points An additional 24 deaths in London hospitals of patients who had tested positive for COVID-19 and an additional 5 where COVID-19 was mentioned on the death certificate were announced in the week ending 27 June 2022. This compares with 40 and 3 for the previous week. A total of 306 deaths in hospitals of patients who had tested positive for COVID-19 and 27 where COVID-19 was mentioned on the death certificate were announced for England as whole. This compares with 301 and 26 for the previous week. The total number of COVID-19 deaths reported in London hospitals of patients who had tested positive for COVID-19 is now 19,102. The total number of deaths in London hospitals where COVID-19 was mentioned on the death certificate is now 1,590. This compares to figures of 119,237 and 8,197 for English hospitals as a whole. Due to the delay between death occurrence and reporting, the estimated number of deaths to this point will be revised upwards over coming days These figures do not include deaths that occurred outside of hospitals. Data from ONS has indicated that the majority (79%) of COVID-19 deaths in London have taken place in hospitals. Recently announced deaths in Hospitals 21 June 22 June 23 June 24 June 25 June 26 June 27 June London No positive test 0 0 1 4 0 0 0 London Positive test 3 7 2 10 0 0 2 Rest of England No positive test 2 6 4 4 0 0 6 Rest of England Positive test 47 49 41 58 6 0 81 16 May 23 May 30 May 06 June 13 June 20 June 27 June London No positive test 14 3 4 0 4 3 5 London Positive test 45 34 55 20 62 40 24 Rest of England No positive test 41 58 33 23 47 23 22 Rest of England Positive test 456 375 266 218 254 261 282 Deaths by date of occurrence 21 June 22 June 23 June 24 June 25 June 26 June 27 June London 20,683 20,686 20,690 20,691 20,692 20,692 20,692 Rest of England 106,604 106,635 106,679 106,697 106,713 106,733 106,742 Interpreting the data The data published by NHS England are incomplete due to: delays in the occurrence and subsequent reporting of deaths deaths occurring outside of hospitals not being included The total deaths reported up to a given point are therefore less than the actual number that have occurred by the same point. Delays in reporting NHS provide the following guidance regarding the delay between occurrence and reporting of deaths: Confirmation of COVID-19 diagnosis, death notification and reporting in central figures can take up to several days and the hospitals providing the data are under significant operational pressure. This means that the totals reported at 5pm on each day may not include all deaths that occurred on that day or on recent prior days. The data published by NHS England for reporting periods from April 1st onward includes both date of occurrence and date of reporting and so it is possible to illustrate the distribution of these reporting delays. This data shows that approximately 10% of COVID-19 deaths occurring in London hospitals are included in the reporting period ending on the same day, and that approximately two-thirds of deaths were reported by two days after the date of occurrence. Deaths outside of hospitals The data published by NHS England does not include deaths that occur outside of hospitals, i.e. those in homes, hospices, and care homes. ONS have published data for deaths by place of occurrence. This shows that, up to 05 August, 79% of deaths in London recorded as involving COVID-19 occurred in hospitals (this compares with 44% for all causes of death). This would suggest that the NHS England data may underestimate overall deaths from COVID-19 by around 20%. Comparison of data sources Note on data sources NHS England provides numbers of patients who have died in hospitals in England and had tested positive for COVID-19, and from 25 April, the number of patients where COVID-19 is mentioned on the death certificate and no positive COVID-19 test result was received. Figures are updated each day at 2pm with deaths reported up to 5pm the previous day. There is a delay between the occurrence of a death to it being captured in the daily reporting. The data can be presented both as reported deaths by day and death occurrences by day. Reported occurrences for recent days should be considered incomplete as likely to be revised upwards as more data becomes available. The location of a death reflects the location of the hospital in which it occurred. Source: NHS England COVID-19 Daily Deaths The Office for National Statistics publishes deaths for England and Wales by the week in which they were registered. Due to the delay between the occurrence of a death and its registration, many deaths that occur in a given week will appear in the data for a subsequent week. For 2018, ONS estimated that 74% of deaths were registered within seven days. Additional delays in registration can occur over public holidays, with significant changes in numbers being observable over Easter and Christmas. The location of a death reflects the usual residence of the deceased. There are some differences in total numbers reported for different geographical levels. The figures published at the local authority level have been used in this analysis. The data is updated each Tuesday at 9.30am with data for the week ending eleven days prior. For the 2020 series, ONS has included the number of deaths where coronavirus (COVID-19) was mentioned on the death certificate. This data includes deaths for all places of occurrence. The ONS started publishing deaths in care homes notified to the Care Quality Commission on 28th April for local authorities in England by date of notification. This data includes an additional week of data compared to the main ONS publication. Source: Deaths registered weekly in England and Wales, provisional, Death registrations and occurrences by local authority, Deaths in care homes notified to the Care Quality Commission, report

Context

Mental Health Services Monthly Statistics

This publication provides the most timely picture available of people using NHS funded secondary mental health, learning disabilities and autism services in England. These are experimental statistics which are undergoing development and evaluation. This information will be of use to people needing access to information quickly for operational decision making and other purposes. More detailed information on the quality and completeness of these statistics is made available later in our Mental Health Bulletin: Annual Report publication series.

• COVID-19 and the production of statistics

Due to the coronavirus illness (COVID-19) disruption, it would seem that this is now starting to affect the quality and coverage of some of our statistics, such as an increase in non-submissions for some datasets. We are also starting to see some different patterns in the submitted data. For example, fewer patients are being referred to hospital and more appointments being carried out via phone/telemedicine/email. Therefore, data should be interpreted with care over the COVID-19 period.

Content

Time period covered Feb 1, 2020 - April 31, 2020

Area covered England

Acknowledgements

reference: Mental Health Services Monthly Statistics

Author: Community and Mental Health Team, NHS Digital
Responsible Statistician: Tom Poupart, Principal Information Analyst
Public Enquiries: Telephone: 0300 303 5678
Email: enquiries@nhsdigital.nhs.uk
Press enquiries should be made to: Media Relations Manager: Telephone: 0300 303 3888

Published by NHS Digital part of the Government Statistical Service Copyright © 2020 Health and Social Care Information Centre. The Health and Social Care Information Centre is a non-departmental body created by statute, also known as NHS Digital.

You may re-use this document/publication (not including logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0.
To view this licence visit To view this licence visit www.nationalarchives.gov.uk/doc/open-government-licence www.nationalarchives.gov.uk/doc/open-government-licence or write to the Information Policy Team, The National Archives, or write to the Information Policy Team, The National Archives, Kew, Richmond, Surrey, TW9 4DU Kew, Richmond, Surrey, TW9 4DU; or email: psi@nationalarchives.gsi.gov.uk or email: psi@nationalarchives.gsi.gov.uk

Cover by-

Inspiration

This dataset is to solve the challenge- UNCOVER COVID-19 Challenge, United Network for COVID Data Exploration and Research. This data is scraped in hopes of solving the task - Mental health impact and support services.

Task Details Can we predict changes in demand for mental health services and how can we ensure access? (by region, social/economic/demographic factors, etc). Are there signs of shifts in mental health challenges across demographies, whether improvements or declines, as a result of COVID-19 and the various measures implement to contain the pandemic?

Multiple linear regression analysis of predictors of change (Δ) in %times in range and CV for blood glucose from pre-lockdown to lockdown for the combined adult and paediatric cohorts (n = 145).

First reported in Wuhan, China, in December 2019, now more than 846,200 confirmed cases of COVID-19 are spread across 187 countries worldwide. The US and several countries in Europe such as Italy, Spain, and Belgium have continued to see a decrease in daily cases. Russia, Brazil, and Latin American countries are seeing increasing trends. India has also seen an increase in the number of new cases reported despite strict distancing measures taken early on.
Special populations analysis covered in the report include the following:
COVID-19 in children may result in systemic multisystem syndrome with severe outcomes.
Childhood routine vaccination rates drop during pandemic.
COVID-19’s impact in pregnant women unclear, though most cases are asymptomatic.
The COVID-19 pandemic could cause an increase in the prevalence of post-traumatic stress disorder (PTSD).
Complications of opioid addiction will be challenging for the management of disease during the COVID-19 pandemic. Read More

Snapshot img

Europe Coronavirus Test Kits Market Size 2024-2028

The coronavirus test kits market in Europe size is forecast to decrease by USD 1.89 billion at a CAGR of -72.5% between 2023 and 2028.

The European coronavirus test kits market is experiencing significant growth due to the increasing demand for rapid diagnostic solutions. The emergence of SARS-CoV-2 variants, such as the Delta variant, has highlighted the importance of accurate and timely testing. Oropharyngeal swabs, nasal swabs, and sputum samples are commonly used for diagnosing COVID-19 infections. Point-of-Care (PoC) kits have gained popularity due to their convenience and quick results. However, the accuracy of diagnostic tests remains a challenge, with the Indian Council of Medical Research (ICMR) and the Health Ministry reporting false positives and negatives. The market is expected to continue its expansion as the world navigates the ongoing pandemic.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The European coronavirus test kits market is witnessing significant growth due to the ongoing pandemic caused by SARS-CoV-2. The demand for test kits is driven by the need for early detection and rapid screening of infected individuals to prevent the spread of the virus within communities. According to the medical device database from GlobalData, RT-PCR tests remain the gold standard for diagnosing SARS-CoV-2 infection. These tests detect viral genetic material from human nasal samples, providing accurate results. However, the time-consuming nature of these tests and the requirement for specialized equipment have led to the emergence of alternative solutions, such as SARS-CoV-2 antigen tests.
Moreover, rapid antigen tests, also known as point-of-care (PoC) kits, offer user-friendly solutions for healthcare systems. These tests provide results within minutes, making them ideal for mass screening in various settings, including schools, workplaces, and airports. The Delta variant and the emerging Omicron variant of SARS-CoV-2 have added to the urgency for effective testing solutions. The European Union has been proactive in addressing this need, with initiatives such as the European Health Union and the EU Digital COVID Certificate system. The European coronavirus test kits market is expected to continue its growth trajectory, driven by the ongoing pandemic and the need for regular testing to ensure public health and safety

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Government
  Non government


Type

  Rapid test kit
  RT-PCR
  Others


Geography

  Europe

    Germany
    UK
    France

By End-user Insights

The government segment is estimated to witness significant growth during the forecast period.

In Europe, various diagnostic techniques are utilized to identify COVID-19 cases, with WHO recommending that countries with limited testing capacity or inexperienced national laboratories send their initial positive and negative samples to five referral laboratories in Europe for confirmatory testing. These laboratories include the German coronavirus diagnostic working group at Charite and Robert Koch Institute in Berlin, Erasmus Medical Center in Rotterdam, the Institute Pasteur in Paris, and the Respiratory Virus Unit at Public Health England. Additionally, several other laboratories in Belgium, Luxembourg, the Netherlands, and Spain offer diagnostic testing support. In the UK, Public Health England (PHE) regional laboratories provide testing facilities alongside WHO referral laboratories. As the world awaits vaccinations and booster doses, public awareness remains crucial. During the flu season, mask mandates and social distancing measures continue to be essential preventative measures.

Get a glance at the market report of share of various segments Request Free Sample

Market Dynamics

Our Europe Coronavirus Test Kits Market researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise in the adoption of the European coronavirus Test Kits Market?

Rising adoption of rapid coronavirus test kits is the key driver of the market.

In Europe, the coronavirus pandemic has put immense pressure on healthcare systems, particularly in terms of diagnostic capabilities. To mitigate this challenge, European governments have prioritized expanding their testing capacity through various means. In 2022, there was a significant push to distribute coronavirus test kits across

Results and clinical sensitivity and specificity of the ActiveXpress+ COVID-19 Complete Testing Kit based on COVID-19 RT-qPCR result in the UK and Peru.

These indicators are designed to accompany the SHMI publication. The SHMI methodology does not make any adjustment for deprivation. This is because adjusting for deprivation might create the impression that a higher death rate for those who are more deprived is acceptable. Patient records are assigned to 1 of 5 deprivation groups (called quintiles) using the Index of Multiple Deprivation (IMD). The deprivation quintile cannot be calculated for some records e.g. because the patient's postcode is unknown or they are not resident in England. Contextual indicators on the percentage of provider spells and deaths reported in the SHMI belonging to each deprivation quintile are produced to support the interpretation of the SHMI. Notes: 1. As of the July 2020 publication, COVID-19 activity has been excluded from the SHMI. The SHMI is not designed for this type of pandemic activity and the statistical modelling used to calculate the SHMI may not be as robust if such activity were included. Activity that is being coded as COVID-19, and therefore excluded, is monitored in the contextual indicator 'Percentage of provider spells with COVID-19 coding' which is part of this publication. 2. Please note that there was a fall in the overall number of spells from March 2020 due to COVID-19 impacting on activity for England and the number has not returned to pre-pandemic levels. Further information at Trust level is available in the contextual indicator ‘Provider spells compared to the pre-pandemic period’ which is part of this publication. 3. There is a shortfall in the number of records for The Princess Alexandra Hospital NHS Trust (trust code RQW). Values for this trust are based on incomplete data and should therefore be interpreted with caution. 4. Frimley Health NHS Foundation Trust (trust code RDU) stopped submitting data to the Secondary Uses Service (SUS) during June 2022 and did not start submitting data again until April 2023 due to an issue with their patient records system. This is causing a large shortfall in records and values for this trust should be viewed in the context of this issue. 5. A number of trusts are now submitting Same Day Emergency Care (SDEC) data to the Emergency Care Data Set (ECDS) rather than the Admitted Patient Care (APC) dataset. The SHMI is calculated using APC data. Removal of SDEC activity from the APC data may impact a trust’s SHMI value and may increase it. More information about this is available in the Background Quality Report. 6. East Kent Hospitals University NHS Foundation Trust (trust code RVV) has a submission issue which is causing many of their patient spells to be duplicated in the HES Admitted Patient Care data. This means that the number of spells for this trust in this dataset are overstated by approximately 60,000, and the trust’s SHMI value will be lower as a result. Values for this trust should therefore be interpreted with caution. 7. Further information on data quality can be found in the SHMI background quality report, which can be downloaded from the 'Resources' section of the publication page.

This publication providers the results from the 2024 Patient-Led Assessments of the Care Environment (PLACE) Programme. PLACE assessments are an annual appraisal of the non-clinical aspects of NHS and independent/private healthcare settings, undertaken by teams made up of staff and members of the public (known as patient assessors). The team must include a minimum of 2 patient assessors, making up at least 50 per cent of the group. PLACE assessments provide a framework for assessing quality against common guidelines and standards in order to quantify the facility’s cleanliness, food and hydration provision, the extent to which the provision of care with privacy and dignity is supported, and whether the premises are equipped to meet the needs of people with dementia or with a disability. The PLACE collection underwent a major national review between 2018 – 2019, significantly revising the question set and guidance documentation. Annual review continues before each programme to ensure this collection remains relevant and delivers its aims. The 2019 established a new baseline, and scores are not comparable with any previously published. From 2022, we enforced minimum patient assessor numbers and ratios, and assessments not meeting this standard were excluded from the national results (and therefore are not comparable to previous datasets). Users should also bear in mind that the 2022 programme was heavily impacted by the covid-19 pandemic (and received fewer completed assessments), so 2023 and 2024 results should not be compared with earlier years.

The Infectious Disease Point-of-care (POC) Diagnostics Market size was valued at USD 15.81 USD Billion in 2023 and is projected to reach USD 24.57 USD Billion by 2032, exhibiting a CAGR of 6.5 % during the forecast period. Recent developments include: January 2023 - Cipla Inc. launched a point-of-care testing device, Cippoint. The device is CE IVD-approved and helps diagnose non-communicable and infectious diseases., February 2022 - Trinity Biotech received approval for its TrinScreen HIV, an HIV screening product, from the World Health Organization (WHO). It is a rapid test providing results in less than 12 minutes from a finger stick drop of blood., October 2021 – Hologic, Inc. announced the launch of the Aptima SARS-CoV-2/Flu Assay, a multiplex COVID-19/flu test, in North America and Europe to detect three respiratory viruses SARS-CoV-2, influenza A, and influenza B., April 2021 – Chembio Diagnostics, Inc. announced the launch of the rapid point-of-care COVID-19 /Flu A&B test. The test provides results within 15 minutes., March 2021 – Roche announced the launch of Cobas SARS-CoV-2 Variant Set 1 Test. This test was developed to detect the COVID-19 variants found in the U.K., South Africa, and Brazil.. Key drivers for this market are: Introduction of Cost-effective Manufacturing Processes to Drive Market Growth. Potential restraints include: Lack of Accuracy Associated with Point-of-care Diagnostics Tests to Reduce Product Adoption . Notable trends are: Increasing Number of Hospitals and ASCs Identified as Significant Market Trend.